Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gamma-PN3 in elderly participants
NCT06562790Phase 1Completed
- Sponsor
- GPN Vaccines
- Start
- Aug 2024
- Primary completion
- Mar 2025
- Modality
- Whole Inactivated Vaccines
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of gamma-pn3 in Pneumococcal pneumonia (PP) (2 arms), sponsored by GPN Vaccines. Primary endpoints: Adverse events at 57 days and Geometric fold increase in IgG titre at 56 days. Started Aug 2024; status: completed.
02
Drugs
gamma-pn3
03
Conditions
Pneumococcal pneumonia (PP)
Beyond the preview
Go deeper on NCT06562790.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06562790.